Search

Zentalis Pharmaceuticals Inc

Fermé

4.19 -15.86

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.9699999999999998

Max

4.96

Chiffres clés

By Trading Economics

Revenu

-136K

-35M

BPA

-0.503

Employés

106

EBITDA

2.2M

-35M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+48.6% upside

Dividendes

By Acuity

Prochains Résultats

11 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

36M

331M

Ouverture précédente

20.05

Clôture précédente

4.19

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 août 2026, 23:56 UTC

MSCI Inc. shares are higher in after-market trading, gaining since Thursday's close despite earlier pulling back from a session high.

6 août 2026, 23:56 UTC

Intercontinental Exchange Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

6 août 2026, 23:56 UTC

General Motors Co. shares remain roughly flat in after-market trading. The stock is near the upper end of its one-month range.

6 août 2026, 23:56 UTC

KeyCorp shares are modestly higher in after-market trading following Thursday's close, with no specific company news identified to explain the price action.

6 août 2026, 23:56 UTC

BWX Technologies shares are higher in after-market hours, following an early spike after the market closed. The stock remains below its 20-day moving average.

6 août 2026, 23:56 UTC

Correlated Moves

Lattice Semiconductor is higher in after-market trading, likely influenced by positive momentum in the semiconductor sector and a significant rise in Microchip Technology's stock.

6 août 2026, 23:56 UTC

Dycom Industries Inc. is trading higher in after-market hours, reflecting a slight gain since Thursday's close, with no specific news identified.

6 août 2026, 23:56 UTC

News

Clear Secure Inc launched a Corporate Memberships program to improve business travel, combining services like CLEAR+ and TSA PreCheck. Shares are trading higher after the announcement.

6 août 2026, 23:56 UTC

Tripadvisor Inc shares are higher in after-market trading, reflecting positive sentiment despite broader market challenges. The stock previously peaked before a slight pullback.

6 août 2026, 23:56 UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

6 août 2026, 23:56 UTC

Correlated Moves

Entergy Corp shares advanced in after-market trading, reflecting a positive trend in the electric utilities sector amid broader market dynamics.

6 août 2026, 23:56 UTC

NRG Energy Inc shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

6 août 2026, 23:56 UTC

News

Shares declined after-hours despite JP Morgan raising price target to $545.

6 août 2026, 23:56 UTC

iShares iBoxx $ High Yield Corporate Bond ETF traded roughly flat after market hours, with mixed performance in global equity indices and a stronger U.S. Dollar.

6 août 2026, 23:56 UTC

Akebia Therapeutics Inc. shares are higher in after-market trading, advancing modestly since Thursday's close amid routine fluctuations within a narrow range.

6 août 2026, 23:56 UTC

Parker-Hannifin Corp shares are higher in after-market hours, recovering from an earlier dip and reflecting a modest uptick since Thursday's close.

6 août 2026, 23:56 UTC

Magnite Inc. shares are trading lower in after-market hours, with no specific news identified. The stock remains above its 20-day moving average.

6 août 2026, 23:52 UTC

News

First Solar supports Section 232 action on polysilicon imports, benefiting U.S. manufacturing. Shares have moved sharply higher in after-market trading.

6 août 2026, 23:51 UTC

Mosaic Co shares traded roughly flat in after-market hours amid a strengthening U.S. Dollar and rising crude oil prices contributing to market volatility.

6 août 2026, 23:51 UTC

Correlated Moves

Patrick Industries Inc shares are higher in after-market trading, reflecting positive sector sentiment and following gains in SiteOne Landscape Supply Inc.

6 août 2026, 23:51 UTC

VF Corp shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

6 août 2026, 23:51 UTC

Exlservice Holdings Inc shares are higher in after-market trading, continuing a recent upward trend and remaining well above their 20-day moving average.

6 août 2026, 23:51 UTC

News

The Invesco Currencyshares Japanese Yen Trust is lower in after-market hours, reflecting broader market movements amid ongoing U.S. and Japan currency interventions.

6 août 2026, 23:51 UTC

Ralph Lauren Corp shares are trading lower in after-market hours. The stock saw notable volatility today amid broader market factors, including a stronger U.S. Dollar.

6 août 2026, 23:51 UTC

Payoneer Global Inc shares are declining in after-market trading, reversing from earlier gains and remaining below the 20-day moving average.

6 août 2026, 23:51 UTC

Conagra Brands Inc shares are higher in after-market hours, reaching a session high and remaining above the 20-day moving average. No specific news was identified.

6 août 2026, 23:51 UTC

Alliant Energy Corp shares advanced during after-market hours, reflecting unusual strength despite being below the 20-day moving average and recent declines.

6 août 2026, 23:51 UTC

UiPath Inc shares are lower in after-market hours following Thursday's close, despite earlier fluctuations. Broader market dynamics may be influencing the decline.

6 août 2026, 23:51 UTC

Greenbrier Companies Inc. shares are lower in after-market trading, continuing a trend of declines over three consecutive sessions amid broader market volatility.

6 août 2026, 23:51 UTC

News

LeMaitre Vascular Inc shares declined in after-market trading, nearing the lower end of their one-month range amid broader market volatility from Middle East supply concerns.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

48.6% hausse

Prévisions sur 12 Mois

Moyen 7.43 USD  48.6%

Haut 11 USD

Bas 4 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

5

Achat

3

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat